PRECLINICAL PHARMACOKINETICS

Donald E. Mager; Murali Ramanathan

doi:10.1002/9780470571224.pse297

PRECLINICAL PHARMACOKINETICS

Pharmaceutical Sciences

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

The preclinical pharmacokinetics of protein pharmaceuticals is distinctively different from small-molecule drugs. Understanding the mechanisms and implications of in vivo disposition of macromolecules provides a means for investigating and designing novel drug candidates and delivery systems to optimize exposure-response relationships or therapeutic efficacy. This article focuses on the different aspects of preclinical pharmacokinetics of protein pharmaceuticals.

Original language	English
Title of host publication	Pharmaceutical Sciences Encyclopedia
Publisher	wiley
Pages	1-26
Number of pages	26
ISBN (Electronic)	9780470571224
DOIs	https://doi.org/10.1002/9780470571224.pse297
State	Published - Jan 1 2010

Keywords

cytochrome p450 enzymes
immunogenicity
pharmacokinetics
protein pharmaceuticals

Access to Document

10.1002/9780470571224.pse297

Cite this

@inbook{8b514288b702460dac4581415b01756d,

title = "PRECLINICAL PHARMACOKINETICS",

abstract = "The preclinical pharmacokinetics of protein pharmaceuticals is distinctively different from small-molecule drugs. Understanding the mechanisms and implications of in vivo disposition of macromolecules provides a means for investigating and designing novel drug candidates and delivery systems to optimize exposure-response relationships or therapeutic efficacy. This article focuses on the different aspects of preclinical pharmacokinetics of protein pharmaceuticals.",

keywords = "cytochrome p450 enzymes, immunogenicity, pharmacokinetics, protein pharmaceuticals",

author = "Mager, \{Donald E.\} and Murali Ramanathan",

note = "Publisher Copyright: {\textcopyright} 2010 John Wiley \& Sons, Inc.",

year = "2010",

month = jan,

day = "1",

doi = "10.1002/9780470571224.pse297",

language = "English",

pages = "1--26",

booktitle = "Pharmaceutical Sciences Encyclopedia",

publisher = "wiley",

}

TY - CHAP

T1 - PRECLINICAL PHARMACOKINETICS

AU - Mager, Donald E.

AU - Ramanathan, Murali

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The preclinical pharmacokinetics of protein pharmaceuticals is distinctively different from small-molecule drugs. Understanding the mechanisms and implications of in vivo disposition of macromolecules provides a means for investigating and designing novel drug candidates and delivery systems to optimize exposure-response relationships or therapeutic efficacy. This article focuses on the different aspects of preclinical pharmacokinetics of protein pharmaceuticals.

AB - The preclinical pharmacokinetics of protein pharmaceuticals is distinctively different from small-molecule drugs. Understanding the mechanisms and implications of in vivo disposition of macromolecules provides a means for investigating and designing novel drug candidates and delivery systems to optimize exposure-response relationships or therapeutic efficacy. This article focuses on the different aspects of preclinical pharmacokinetics of protein pharmaceuticals.

KW - cytochrome p450 enzymes

KW - immunogenicity

KW - pharmacokinetics

KW - protein pharmaceuticals

UR - https://www.scopus.com/pages/publications/105031343645

U2 - 10.1002/9780470571224.pse297

DO - 10.1002/9780470571224.pse297

M3 - Chapter

AN - SCOPUS:105031343645

SP - 1

EP - 26

BT - Pharmaceutical Sciences Encyclopedia

PB - wiley

ER -

PRECLINICAL PHARMACOKINETICS

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this